Selventa and Rosa in early-stage drug discovery deal
CAMBRIDGE, Mass.—Selventa, which evolved from Genstruct Inc., has formed a strategic scientific alliance with Rosa and Co., a drug development advisory firm with expertise in drug-disease modeling and simulation. According to the companies, the alliance will bring together established analytical capabilities of both companies to better inform drug discovery and development decisions. The new partnership will provide access to a combination of knowledge assets, proprietary data, physiologic model libraries and expertise in disease areas such as oncology, immunology, respiratory, inflammatory and metabolic diseases. Additional details were not released.